Andere talen Resverlogix Corp.

Aandelen

RVX

CA76128M1086

Biotechnologie & Medisch Onderzoek

Vertraagde tijd Toronto S.E. Andere beurzen 15:35:51 19-01-2026			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,1000 ^CAD	0,00%		+5,26%	-

19/11	Resverlogix benoemt Bradley Glass tot lid van de Raad van Bestuur	CI
14/11	Resverlogix Corp. rapporteert resultaten derde kwartaal en eerste negen maanden 2025	CI

Andere talen

19/11	Resverlogix Appoints Bradley Glass to Board of Directors
18/11	Resverlogix Appoints Bradley Glass to Board of Directors
14/11	Resverlogix : MD&A Q3 2025
14/11	Resverlogix : Financial Statement September 30, 2025
14/11	Resverlogix Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
14-08-25	Resverlogix : MD&A Q2 2025
14-08-25	Resverlogix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
30-06-25	Resverlogix Announces Voting Results from the 2025 Meeting of Shareholders
23-05-25	Resverlogix : Annual Meeting of Shareholders - Notice and Access
14-05-25	Resverlogix : Financial Statement Q1 2025
14-05-25	Resverlogix : MD&A Q1 2025
14-05-25	Resverlogix Corp. Reports Earnings Results for the First Quarter Ended March 31, 2025
01-04-25	Resverlogix : MD&A Q4 2024
01-04-25	Resverlogix : Financial Statement Q4 2024
01-03-25	Resverlogix Corp. Auditor Raises 'Going Concern' Doubt
13-11-24	Resverlogix : Financial Statement Q3 2024
13-11-24	Resverlogix : MD&A Q3 2024
13-11-24	Resverlogix Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
03-09-24	Numerous Independent Groups Presented Data that Supports Apabetalone's Potential Cardioprotective Benefits at European Society of Cardiology Congress 2024
15-08-24	Resverlogix : MD&A Q2 2024
15-08-24	Resverlogix : Financial Statement Q2 2024
15-08-24	Resverlogix Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024
01-08-24	Resverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension
01-08-24	Resverlogix : Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture Extension
16-07-24	Resverlogix Provides Update Regarding Two-Year Extension of Debenture and Elimination of Conversion Privileges

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripten Persberichten Officiële publicaties Andere talen MarketScreener-artikels MarketScreener-analyses Ideeën voor de handel

Andere talen Resverlogix Corp.

Aandelen

RVX

CA76128M1086

Biotechnologie & Medisch Onderzoek

Andere talen

Filters